electroCore (NASDAQ:ECOR) Releases Quarterly Earnings Results, Meets Estimates

Key Points

• electroCore reported EPS of ($0.59) that matched estimates and delivered a record quarter with $9.6M revenue (+43% YoY), an 87% gross margin, and an adjusted EBITDA loss narrowed to $2.3M.
• The VA remains the primary growth driver — prescription device revenue rose 48% with ~15,000 VA patients (~2.5% penetration), while consumer channel Truvaga revenue grew ~38% to ~$1.5M as management pushes higher per‑site utilization and next‑gen mobile features.
• Cash and profitability are under pressure: cash fell to ~$8.8M from $11.6M, GAAP net loss widened to $5.3M (including $1.9M one‑time transition costs), Q1 was the company’s highest burn quarter, and management is evaluating capital options.

electroCore (NASDAQ:ECOR - Get Free Report) posted its earnings results on Wednesday. The company reported ($0.59) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.59), Zacks reports. The business had revenue of $9.58 million during the quarter, compared to analysts' expectations of $9.01 million. electroCore had a negative return on equity of 1,956.38% and a negative net margin of 43.60%.

Here are the key takeaways from electroCore's conference call:

• Record quarter — $9.6M revenue (+43% YoY) with an 87% gross margin and a 24% improvement in adjusted EBITDA loss to $2.3M, which management cites as evidence of emerging operating leverage.
• The VA remains the largest growth driver — prescription device revenue rose 48% and ~15,000 VA patients have received devices (estimated ~2.5% penetration), signaling substantial upside as the new COO focuses on increasing per-site utilization.
• Clinical and regulatory catalysts could expand indications — PTSD has Breakthrough Device designation, Acacia trial enrollment is underway, and recent publications support NVNS benefits, which management plans to aggregate for a potential PTSD label.
• Consumer channel momentum — Truvaga revenue was ~$1.5M (+38% YoY) with improved ROAS (~2.37) and a January U.K. soft launch, while next‑gen mobile features are being developed to pursue recurring revenue.
• Cash and profitability pressure — cash and equivalents fell to ~$8.8M from $11.6M, Q1 was the company’s highest burn quarter, GAAP net loss widened to $5.3M (including $1.9M one‑time transition costs), and management is evaluating capital options.

electroCore Stock Performance

NASDAQ ECOR opened at $6.66 on Thursday. electroCore has a 52 week low of $4.16 and a 52 week high of $8.64. The stock's 50 day moving average price is $6.60 and its two-hundred day moving average price is $5.87. The stock has a market capitalization of $53.81 million, a price-to-earnings ratio of -4.04 and a beta of 0.68.

Insider Buying and Selling at electroCore

In other news, Director Daniel S. Goldberger sold 16,072 shares of the firm's stock in a transaction that occurred on Friday, April 10th. The shares were sold at an average price of $6.02, for a total transaction of $96,753.44. Following the completion of the transaction, the director directly owned 291,471 shares of the company's stock, valued at $1,754,655.42. This trade represents a 5.23% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 13.80% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the business. DRW Securities LLC bought a new position in electroCore in the fourth quarter valued at $264,000. Jane Street Group LLC lifted its position in electroCore by 114.4% during the 1st quarter. Jane Street Group LLC now owns 36,726 shares of the company's stock worth $246,000 after buying an additional 19,599 shares in the last quarter. NewEdge Advisors LLC boosted its stake in shares of electroCore by 857.9% during the 1st quarter. NewEdge Advisors LLC now owns 161,955 shares of the company's stock worth $1,083,000 after buying an additional 145,047 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new position in shares of electroCore during the 1st quarter worth about $153,000. Finally, Two Sigma Investments LP grew its holdings in shares of electroCore by 20.8% in the 3rd quarter. Two Sigma Investments LP now owns 24,603 shares of the company's stock valued at $122,000 after acquiring an additional 4,231 shares in the last quarter. Institutional investors and hedge funds own 26.74% of the company's stock.

Analyst Upgrades and Downgrades

ECOR has been the subject of several research analyst reports. HC Wainwright reduced their price target on shares of electroCore from $25.00 to $18.00 and set a "buy" rating for the company in a report on Monday, January 26th. Weiss Ratings restated a "sell (d-)" rating on shares of electroCore in a report on Friday, March 27th. Zacks Research raised shares of electroCore from a "strong sell" rating to a "hold" rating in a research report on Friday, March 27th. Finally, raised shares of electroCore to a "strong-buy" rating in a research note on Tuesday, February 3rd. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $18.00.

About electroCore

electroCore, Inc is a commercial-stage bioelectronic medicine company headquartered in Rockaway, New Jersey. The company specializes in the development and commercialization of non-invasive vagus nerve stimulation (nVNS) therapies designed to address a variety of neurological and inflammatory conditions. Established in 2006, electroCore has focused its efforts on translating neuromodulation science into a compact, patient-administered treatment device.

The company's lead product, gammaCore®, is a handheld, battery-powered device that delivers nVNS through the skin to the cervical branch of the vagus nerve.